This application is a continuation of Sack, U.S. Patent Appl. Publ. No. 2019/0282372, published Sep. 19, 2019, and entitled Implant with Deployable Blades, which is a continuation of Sack, U.S. Pat. No. 10,307,265, issued Jun. 4, 2019, and entitled Implant with Deployable Blades, the entire disclosure of each of the above is incorporated herein by reference.
The embodiments are generally directed to implants for supporting bone growth in a patient.
A variety of different implants are used in the body. Implants used in the body to stabilize an area and promote bone ingrowth provide both stability (i.e. minimal deformation under pressure over time) and space for bone ingrowth.
Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical treatment method used for the treatment of various morbidities such as degenerative disc disease, spondylolisthesis (slippage of a vertebra), spinal stenosis, scoliosis, fracture, infection or tumor. The aim of the spinal fusion procedure is to reduce instability and thus pain.
In preparation for the spinal fusion, most of the intervertebral disc is removed. An implant, the spinal fusion cage, may be placed between the vertebra to maintain spine alignment and disc height. The fusion (i.e. bone bridge) occurs between the endplates of the vertebrae.
In one aspect, an implant includes a body with a first axis. The implant also includes a blade having a retracted position in the body and an extended position where the blade extends outwardly from the body. The implant also includes a blade actuating member that can translate through the body in directions parallel to the first axis. The blade actuating member includes a channel, where the channel extends between a superior surface and an inferior surface of the blade actuating member, and where the channel defines a first channel direction and an opposing second channel direction. The blade includes a protruding portion configured to fit within the channel. When the blade actuating member is moved in a first direction along the first axis, the protruding portion follows the channel in the first channel direction and the blade moves towards the extended position. When the blade actuating member is moved in a second direction opposite the first direction, the protruding portion follows the channel in the second channel direction and the blade moves towards the retracted position.
In another aspect, an implant includes a body having a first axis. The implant also includes a blade having a retracted position in the body and an extended position where the blade extends outwardly from the body. The blade has an outer edge, an inner edge, a first lateral edge and a second lateral edge. The first lateral edge of the blade and the second lateral edge of the blade are in contact with the body. The blade also has a distal face and a proximal face. The implant includes a blade actuating member that can translate through the body in directions parallel to the first axis. A portion of the proximal face is in contact with the blade actuating member. The distal face is disposed away from the body. The blade actuating member can move the blade between the retracted position and the extended position.
In another aspect, an implant includes an outer structure having a first axis. The implant also includes a blade having a retracted position in the outer structure and an extended position where the blade extends outwardly from the outer structure. The implant also includes a blade actuating member that can translate through the outer structure in directions parallel to the first axis. The blade actuating member is coupled to the blade and can move the blade between the retracted position and the extended position. The outer structure includes a first end having a threaded opening and a guide opening adjacent the threaded opening, where the guide opening receives a driven end of the blade actuating member. The implant also includes a locking screw secured within the threaded opening. The locking screw can be rotated between an unlocked rotational position in which the driven end of the blade actuating member can pass through the guide opening and a locked rotational position, in which the drive end of the blade actuating member is prevented from moving through the guide opening.
Other systems, methods, features and advantages of the embodiments will be, or will become, apparent to one of ordinary skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description and this summary, be within the scope of the embodiments, and be protected by the following claims.
The embodiments can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, with emphasis instead being placed upon illustrating the principles of the embodiments. Moreover, in the figures, like reference numerals designate corresponding parts throughout the different views.
The embodiments described herein are directed to an implant for use in a spine. The embodiments include implants with a body and one or more blades. In addition to the various provisions discussed below, any embodiments may make use of any of the body/support structures, blades, actuating members or other structures disclosed in Duffield et al., U.S. Pat. No. 9,707,100, issued Jul. 18, 2017, and titled “Interbody Fusion Device and System for Implantation,” which is hereby incorporated by reference in its entirety. For purposes of convenience, the Duffield patent will be referred to throughout the application as “The Fusion Device Application”.
Introduction to the Implant
In some embodiments, implant 100 may be inserted using a lateral interbody fusion (LIF) surgical procedure. In some cases, implant 100 could be inserted through a small incision in the side of the body. Exemplary techniques that could be used include, but are not limited to: DLIF® (Direct Lateral Interbody Fusion), XLIF® (eXtreme Lateral Interbody Fusion), and transpsoas interbody fusion.
For purposes of clarity, reference is made to various directional adjectives throughout the detailed description and in the claims. As used herein, the term “anterior” refers to a side or portion of an implant that is intended to be oriented towards the front of the human body when the implant has been placed in the body. Likewise, the term “posterior” refers to a side or portion of an implant that is intended to be oriented towards the back of the human body following implantation. In addition, the term “superior” refers to a side or portion of an implant that is intended to be oriented towards a top (e.g., the head) of the body while “inferior” refers to a side or portion of an implant that is intended to be oriented towards a bottom of the body. Reference is also made herein to “lateral” sides or portions of an implant, which are sides or portions facing along a lateral direction of the body.
Reference is also made to directions or axes that are relative to the implant itself, rather than to its intended orientation with regards to the body. For example, the term “distal” refers to a part that is located further from a center of an implant, while the term “proximal” refers to a part that is located closer to the center of the implant. As used herein, the “center of the implant” could be the center of mass and/or a central plane and/or another centrally located reference surface.
An implant may also be associated with various axes. Referring to
An implant may also be associated with various reference planes or surfaces. As used herein, the term “median plane” refers to a vertical plane which passes from the anterior side to the posterior side of the implant, dividing the implant into right and left halves, or lateral halves. As used herein, the term “transverse plane” refers to a horizontal plane located in the center of the implant that divides the implant into superior and inferior halves. As used herein, the term “coronal plane” refers to a vertical plane located in the center of the implant that divides the implant into anterior and posterior halves. In some embodiments, the implant is symmetric about two planes, such as the median and the transverse plane.
Embodiments of an implant may include provisions for anchoring the implant into adjacent vertebral bodies. In some embodiments, an implant may include one or more anchoring members. In the embodiment of
An implant with blades can include provisions for moving the blades with respect to an outer structure of the implant. In some embodiments, an implant includes a blade actuating member that engages with one or more blades to extend and/or retract the blades from the surfaces of the implant. In the embodiment shown in
An implant can include provisions for locking the position of one or more elements of the implant. In embodiments where the position of a blade actuating member can be changed, an implant can include provisions for locking the actuating member in a given position, thereby also locking one or more blades in a given position. In the embodiment shown in
Embodiments can include one or more fasteners that help attach a body to a cap. In some embodiments, pins, screws, nails, bolts, clips, or any other kinds of fasteners could be used. In the embodiment shown in
Operation
The embodiments described herein provide an implant that can move from a first position (the “insertion position”), which allows the implant to maintain a low profile, to a second position (the “impaction position” or the “deployed position”), that deploys the blades and inserts them into the proximal superior and inferior vertebral bodies. While the implant is in the first (insertion) position, the blades of the device may be retracted within the body of the implant (i.e., the blades may themselves be in a “retracted position”). In the second (deployed) position of the implant, the blades extend superiorly (or cranially) or inferiorly (or caudally) beyond the implant and into the vertebral bodies to prevent the implant from moving out of position over time. Thus, the blades themselves may be said to be in an “extended position” or “deployed position”. When the blades are deployed, the implant resists left to right rotation and resists flexion and/or extension. It may be appreciated that although the blades may approximately move in vertical directions (i.e., the superior and inferior directions), the actual direction of travel may vary from one embodiment to another. For example, in some embodiments the blades may be slightly angled within the implant and may deploy at slight angles to a vertical direction (or to the inferior/superior directions).
In some embodiments, one or more blades could be deployed at a slight angle, relative to the normal directions on the superior and inferior surfaces of the implant. In some embodiments, one or more blades could be oriented at an angle between 0 and 30 degrees. In other embodiments, one or more blades could be oriented at an angle that is greater than 30 degrees. In the exemplary embodiment shown in
The extension of each blade could vary in different embodiments. In some embodiments, a blade could extend outwardly by a length between 0 and 100% of the depth of an implant. In still other embodiments, combined blade height could extend outwardly by a length between 100 and 130% of the depth of an implant. In the exemplary embodiment shown in
Blades and Blade Actuating Member
In different embodiments, the geometry of a blade could vary. In some embodiments, a blade could have a substantially planar geometry such that the distal face and the proximal face of the blade are each parallel with a common plane. In other embodiments, a blade could be configured with one or more bends. In some embodiments, a blade can have a channel-like geometry (ex. “C”-shaped or “S”-shaped). In the embodiment shown in
In the exemplary embodiment, the outer edge 400 is a penetrating edge configured to be implanted within an adjacent vertebral body. To maximize penetration, outer edge 400 may be sharpened so that blade 241 has an angled surface 409 adjacent outer edge 400. Moreover, in some embodiments, first lateral edge 404 and second lateral edge 406 are also sharpened in a similar manner to outer edge 400 and may act as extensions of outer edge 400 to help improve strength and penetration.
A blade can include provisions for coupling with a blade actuating member. In some embodiments, a blade can include a protruding portion. In some embodiments, the protruding portion can extend away from a face of the blade and may fit within a channel in a blade actuating member. Referring to
A protruding portion may be oriented at an angle on a blade so as to fit with an angled channel in a blade actuating member. In the embodiment of
Although the above discussion is directed to first blade 241, it may be appreciated that similar principles apply for second blade 242. In particular, in some embodiments, second blade 242 may have a substantially identical geometry to first blade 241.
In some embodiments, driven end 262 can include one or more engaging features. For example, driven end 262 can include a threaded opening 267, as best seen in
Blade engaging portion 322 may comprise a superior surface 330, an inferior surface 332, a first side surface 334 and a second side surface 336. Here, first side surface 334 may be an anterior facing side and second side surface 336 may be a posterior facing side. In other embodiments, however, first side surface 334 could be a posterior facing side and second side surface 336 could be an anterior facing side.
A blade actuating member can include provisions for coupling with one or more blades. In some embodiments, a blade actuating member can include one or more channels. In the exemplary embodiment of
Each channel is seen to extend at an angle between superior surface 330 and inferior surface 332 of a blade engaging portion 322. For example, as best seen in
In different embodiments, the angle of each channel could be selected to provide proper blade extension for varying implant sizes. As used herein, the angle of a channel is defined to be the angle formed between the channel and a transverse plane of the blade actuating member. In the embodiment of
In different embodiments, the angle of each channel could vary. In some embodiments, a channel could be oriented at any angle between 15 and 75 degrees. In other embodiments, a channel could be oriented at any angle between 35 and 65 degrees. Moreover, in some embodiments, the angle of a channel may determine the angle of a protruding portion in a corresponding blade. For example, the angle 459 formed between protruding portion 450 and inner edge 402 of blade 241 (see
As seen in
In some embodiments, blade engaging portion 322 may be contoured at the superior and inferior surfaces to resist subsidence and allow maximum blade deployment depth. This geometry may also help to keep the blade engaging portion 322 centered between vertebral endplates. As an example, the contouring of superior surface 330 and inferior surface 332 in the present embodiment is best seen in the enlarged cross-sectional view of
Each channel may be associated with a first channel direction and an opposing second channel direction. For example, as best seen in
With first protruding portion 450 of first blade 241 disposed in first channel 350, first protruding portion 450 can slide in first channel direction 460 or second channel direction 462. As first protruding portion 450 slides in first channel direction 460, first blade 241 moves vertically with respect to blade actuating member 260 such that first blade 241 extends outwardly on a superior side of implant 100 (see
As shown in the cross section of
In some embodiments, each protruding portion forms a sliding dovetail connection or joint with a corresponding channel. Using dovetail tracks on the blade actuating member and corresponding dovetail features on the posterior and anterior blades allows axial movement along the angle of inclination while preventing disengagement under loads encountered during blade impaction and retraction. For example, in
It may be appreciated that in other embodiments, the geometry of the interconnecting parts between a blade and a blade actuating member could be reversed. For example, in another embodiment, a blade could comprise one or more channels and a blade actuating member could include corresponding protrusions to fit in the channels. In such embodiments, both the protruding portion of the blade actuating member and the channels in the blades could have corresponding dovetail geometries.
Body and Cap
In some embodiments, the posterior and anterior sides of a body may both have a truss-like or lattice-like geometry. In other embodiments, the posterior and/or anterior sides could be configured as solid walls with one or more openings. In the exemplary embodiment shown in
The configuration of supports 500 shown for the embodiment of
In other embodiments, a body may not have a truss or lattice-like geometry. For example, an alternative design for a body 550 is shown in
Embodiments can also include one or more blade retaining portions. A blade retaining portion may receive any part of a blade, including one or more edges and/or faces of the blade. In one embodiment, a body includes blade retaining portions to receive the lateral edges of each blade. As seen in
As previously discussed, cap 220 may include an opening 224 to receive a locking screw or other fastener. Additionally, cap 220 may include guide opening 222 that receives a portion of blade actuating member 260. In some embodiments, guide opening 222 may have a shape that matches the cross-sectional shape of a driven portion of a blade actuating member. In some embodiments, both guide opening 222 and driven shaft portion 320 of blade actuating member 260 have rectangular cross-sectional shapes. This configuration may allow axial motion, but control rotational and angular loads that could result during blade impaction as exemplified in
In some embodiments, cap 220 may include attachment points for an insertion instrument. For example, as seen in
As seen in
Three Point Attachment
Referring to
In different embodiments, the cross-sectional geometry of channels in one or more blade retaining portions could vary. In some embodiments, the cross-sectional geometry could be rounded. In the embodiment shown in
In some embodiments, the lateral edges of each blade may remain in the tracks or channels of each blade retaining portion while the blades are retracted to prevent bone graft material from restricting free deployment of the blades.
Sliding Connection
Using an interlocking joint, such as a dovetail sliding joint, to connect the blades and a blade actuating member helps prevent the blades from decoupling from the blade actuating member during impact. Additionally, with an interlocking joint the blade actuating member can be used to retract the blades.
In
Using this configuration, the forces deploying the blades are balanced through the blade actuating member 260 in order to minimize friction and binding between driven shaft portion 320 and opening 222 in cap 220 (see
In
Referring to
Locking Screw
Rotation restricting groove 289 may include a first groove end 293 and a second groove end 295 (see
As seen in
It may be appreciated that in some embodiments a blade actuating member (e.g., blade actuating member 260) may function to support adjacent vertebral bodies. This is can be accomplished by using a blade actuating member with a height similar to the height of the outer support structure so that the superior and inferior surfaces of the blade actuating member may come into contact with the vertebral bodies following implantation. Since the blade actuating member functions as a load bearing structure within the implant, this may free up additional space in the implant otherwise occupied by additional support structures, thereby increasing the internal volume available for bone graft or BGPMs.
Implant Dimensions
In different embodiments, the size of an implant could vary. In some embodiments, an implant could have any length. Embodiments could have lengths ranging from 40 mm to 60 mm. In some cases, a manufacturer could provide multiple implant options with lengths varying between 40 mm and 60 mm in 5 mm increments. In some embodiments, an implant could have any height. Embodiments could have a height ranging from 8 mm to 16 mm. In some cases, a manufacturer could provide implants with heights varying from 8 mm to 16 mm in 2 mm increments. Embodiments could have widths (i.e., size along the posterior-anterior axis) of 18 mm, 22 mm, 26 mm as well as other sizes.
Embodiments can also be constructed with various lordosis angles, that is, angles of incline between the posterior and anterior sides. Embodiments could be configured with lordosis angles of 8, 15 and 20 degrees, for example. In other embodiments, other lordosis angles could be used for an implant.
Alignment Features
Embodiments may optionally include one or more alignment features. Exemplary alignment features include, but are not limited to, windows for fluoroscopy positioning, windows for blade deployment validation, windows for aligning a blade actuating member with one or more blades, as well as various other kinds of alignment features. Referring to
Some embodiments may also include one or more stroke limiting stops. For example, the embodiment of implant 100 shown in
Materials
The various components of an implant may be fabricated from biocompatible materials suitable for implantation in a human body, including but not limited to, metals (e.g. titanium, titanium alloy, stainless steel, cobalt-chrome, or other metals), synthetic polymers (e.g. PEEK or PEKK), ceramics, and/or their combinations, depending on the particular application and/or preference of a medical practitioner.
Generally, the implant can be formed from any suitable biocompatible, non-degradable material with sufficient strength. Typical materials include, but are not limited to, titanium, biocompatible titanium alloys (e.g. Titanium Aluminides (including gamma Titanium Aluminides), Ti6—Al4-V ELI (ASTM F 136 and ASTM F 3001), or Ti6—Al4-V (ASTM F 1108, ASTM F 1472, and ASTM F 2989) and inert, biocompatible polymers, such as polyether ether ketone (PEEK) (e.g. PEEK-OPTIMA®, Invibio Inc, Zeniva®, Solvay Inc., or others). Optionally, the implant contains a radiopaque marker to facilitate visualization during imaging when constructed of radiolucent biomaterials.
In different embodiments, processes for making an implant can vary. In some embodiments, the entire implant may be manufactured and assembled via traditional and CNC machining, injection-molding, cast or injection molding, insert-molding, co-extrusion, pultrusion, transfer molding, overmolding, compression molding, 3-Dimensional (3-D) printing, dip-coating, spray-coating, powder-coating, porous-coating, milling from a solid stock material and their combinations.
In one embodiment, body 200 may be produced by Direct Metal Laser Sintering (DMLS) using powder Ti—6Al-4V ELI, and then traditional or CNC machined in specific locations to precise dimensions. Moreover, in one embodiment, blade actuating member 260, first blade 241, second blade 242, cap 220, pins 290 and locking screw 280 may also be made of a material including titanium.
Implantation
Some embodiments may use a bone growth promoting material, including bone graft or bone graft substitute material. As used herein, a “bone growth promoting material” (BGPM) is any material that helps bone growth. Bone growth promoting materials may include provisions that are freeze dried onto a surface or adhered to the metal through the use of linker molecules or a binder. Examples of bone growth promoting materials are any materials including bone morphogenetic proteins (BMPs), such as BMP-1, BMP-2, BMP-4, BMP-6, and BMP-7. These are hormones that convert stem cells into bone forming cells. Further examples include recombinant human BMPs (rhBMPs), such as rhBMP-2, rhBMP-4, and rhBMP-7. Still further examples include platelet derived growth factor (PDGF), fibroblast growth factor (FGF), collagen, BMP mimetic peptides, as well as RGD peptides. Generally, combinations of these chemicals may also be used. These chemicals can be applied using a sponge, matrix or gel.
Some bone growth promoting materials may also be applied to an implantable prosthesis through the use of a plasma spray or electrochemical techniques. Examples of these materials include, but are not limited to, hydroxyapatite, beta tri-calcium phosphate, calcium sulfate, calcium carbonate, as well as other chemicals.
A bone growth promoting material can include, or may be used in combination with a bone graft or a bone graft substitute. A variety of materials may serve as bone grafts or bone graft substitutes, including autografts (harvested from the iliac crest of the patient's body), allografts, demineralized bone matrix, and various synthetic materials.
Some embodiments may use autograft. Autograft provides the spinal fusion with calcium collagen scaffolding for the new bone to grow on (osteoconduction). Additionally, autograft contains bone-growing cells, mesenchymal stem cells and osteoblast that regenerate bone. Lastly, autograft contains bone-growing proteins, including bone morphogenic proteins (BMPs), to foster new bone growth in the patient.
Bone graft substitutes may comprise synthetic materials including calcium phosphates or hydroxyapatites, stem cell containing products which combine stem cells with one of the other classes of bone graft substitutes, and growth factor containing matrices such as INFUSE® (rhBMP-2-containing bone graft) from Medtronic, Inc.
It should be understood that the provisions listed here are not meant to be an exhaustive list of possible bone growth promoting materials, bone grafts or bone graft substitutes.
In some embodiments, BGPM may be applied to one or more outer surfaces of an implant. In other embodiments, BGPM may be applied to internal volumes within an implant. In still other embodiments, BGPM may be applied to both external surfaces and internally within an implant.
While various embodiments have been described, the description is intended to be exemplary, rather than limiting, and it will be apparent to those of ordinary skill in the art that many more embodiments and implementations are possible that are within the scope of the embodiments. Although many possible combinations of features are shown in the accompanying figures and discussed in this detailed description, many other combinations of the disclosed features are possible. Any feature of any embodiment may be used in combination with, or substituted for, any other feature or element in any other embodiment unless specifically restricted. Therefore, it will be understood that any of the features shown and/or discussed in the present disclosure may be implemented together in any suitable combination. Accordingly, the embodiments are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.
Number | Name | Date | Kind |
---|---|---|---|
4554914 | Kapp et al. | Nov 1985 | A |
4599086 | Doty | Jul 1986 | A |
4636217 | Ogilvie et al. | Jan 1987 | A |
4892545 | Day | Jan 1990 | A |
5443467 | Biedermann | Aug 1995 | A |
5522899 | Michelson | Jun 1996 | A |
5609635 | Michelson | Mar 1997 | A |
5653708 | Howland | Aug 1997 | A |
5667508 | Errico | Sep 1997 | A |
5683394 | Rinner | Nov 1997 | A |
5702391 | Lin | Dec 1997 | A |
5776199 | Michelson | Jul 1998 | A |
5800547 | Schaefer et al. | Sep 1998 | A |
5800550 | Sertich | Sep 1998 | A |
5989254 | Katz | Nov 1999 | A |
6102949 | Biedermann et al. | Aug 2000 | A |
6102950 | Vaccaro | Aug 2000 | A |
6113601 | Tatar | Sep 2000 | A |
6113638 | Williams et al. | Sep 2000 | A |
6179873 | Zientek | Jan 2001 | B1 |
6251140 | Marino | Jun 2001 | B1 |
6302914 | Michelson | Oct 2001 | B1 |
6371987 | Weiland et al. | Apr 2002 | B1 |
6447544 | Michelson | Sep 2002 | B1 |
6447546 | Bramlet et al. | Sep 2002 | B1 |
6447547 | Michelson | Sep 2002 | B1 |
6454805 | Baccelli et al. | Sep 2002 | B1 |
6478823 | Michelson | Nov 2002 | B1 |
6520993 | James et al. | Feb 2003 | B2 |
6527803 | Crozet | Mar 2003 | B1 |
6565565 | Yuan | May 2003 | B1 |
6645207 | Dixon | Nov 2003 | B2 |
6652526 | Arafiles | Nov 2003 | B1 |
6656181 | Dixon | Dec 2003 | B2 |
6726720 | Ross | Apr 2004 | B2 |
6733535 | Michelson | May 2004 | B2 |
6755829 | Bono | Jun 2004 | B1 |
6767367 | Michelson | Jul 2004 | B1 |
6770096 | Bolger et al. | Aug 2004 | B2 |
6786903 | Lin | Sep 2004 | B2 |
6800092 | Williams et al. | Oct 2004 | B1 |
6896677 | Lin | May 2005 | B1 |
6923830 | Michelson | Aug 2005 | B2 |
6926737 | Jackson | Aug 2005 | B2 |
6981975 | Michelson | Jan 2006 | B2 |
6986771 | Paul | Jan 2006 | B2 |
6989011 | Paul | Jan 2006 | B2 |
7066961 | Michelson | Jun 2006 | B2 |
7081117 | Bono | Jul 2006 | B2 |
7112206 | Michelson | Sep 2006 | B2 |
7125426 | Moumene | Oct 2006 | B2 |
7141051 | Janowski | Nov 2006 | B2 |
7214243 | Taylor | May 2007 | B2 |
7217293 | Branch, Jr. | May 2007 | B2 |
7223289 | Trieu et al. | May 2007 | B2 |
7264621 | Coates | Sep 2007 | B2 |
7318839 | Malberg et al. | Jan 2008 | B2 |
7338491 | Baker | Mar 2008 | B2 |
7361195 | Schwartz et al. | Apr 2008 | B2 |
7465317 | Malberg et al. | Dec 2008 | B2 |
7503924 | Lee | Mar 2009 | B2 |
7503933 | Michelson | Mar 2009 | B2 |
7559942 | Paul | Jul 2009 | B2 |
7569074 | Eisermann | Aug 2009 | B2 |
7594931 | Louis | Sep 2009 | B2 |
7594932 | Aferzon et al. | Sep 2009 | B2 |
7604656 | Shluzas | Oct 2009 | B2 |
7608095 | Yuan | Oct 2009 | B2 |
7655046 | Dryer | Feb 2010 | B2 |
7678137 | Butler | Mar 2010 | B2 |
7704279 | Moskowitz et al. | Apr 2010 | B2 |
7727279 | Zipnick et al. | Jun 2010 | B2 |
7727280 | McLuen | Jun 2010 | B2 |
7731749 | Biedermann | Jun 2010 | B2 |
7731751 | Butler et al. | Jun 2010 | B2 |
7731753 | Reo et al. | Jun 2010 | B2 |
7744649 | Moore | Jun 2010 | B2 |
7749274 | Razian | Jul 2010 | B2 |
7758644 | Trieu | Jul 2010 | B2 |
7766946 | Bailly | Aug 2010 | B2 |
7766967 | Francis | Aug 2010 | B2 |
7771475 | Michelson | Aug 2010 | B2 |
7776067 | Jackson | Aug 2010 | B2 |
7780703 | Yuan | Aug 2010 | B2 |
7789914 | Michelson | Sep 2010 | B2 |
7811310 | Baker | Oct 2010 | B2 |
7819901 | Yuan | Oct 2010 | B2 |
7833252 | Justis | Nov 2010 | B2 |
7842073 | Richelsoph | Nov 2010 | B2 |
7846188 | Moskowitz et al. | Dec 2010 | B2 |
7857857 | Kim | Dec 2010 | B2 |
7867257 | Na | Jan 2011 | B2 |
7879099 | Zipnick et al. | Feb 2011 | B2 |
7883542 | Zipnick et al. | Feb 2011 | B2 |
7909856 | Yuan | Mar 2011 | B2 |
7909872 | Zipnick et al. | Mar 2011 | B2 |
7942903 | Moskowitz et al. | May 2011 | B2 |
7942910 | Doubler | May 2011 | B2 |
7942911 | Doubler | May 2011 | B2 |
7951173 | Hammill, Sr. | May 2011 | B2 |
7951174 | Kwak | May 2011 | B2 |
7951180 | Moskowitz et al. | May 2011 | B2 |
7955359 | Matthis | Jun 2011 | B2 |
7955363 | Richelsoph | Jun 2011 | B2 |
7967850 | Jackson | Jun 2011 | B2 |
7972363 | Moskowitz et al. | Jul 2011 | B2 |
7972365 | Michelson | Jul 2011 | B2 |
7998211 | Baccelli et al. | Aug 2011 | B2 |
8012186 | Pham | Sep 2011 | B2 |
8021430 | Michelson | Sep 2011 | B2 |
8034086 | Iott | Oct 2011 | B2 |
8038702 | Yuan | Oct 2011 | B2 |
8048124 | Chin | Nov 2011 | B2 |
8057519 | Justis | Nov 2011 | B2 |
8062340 | Berrevoets | Nov 2011 | B2 |
8062374 | Markworth et al. | Nov 2011 | B2 |
8062375 | Glerum | Nov 2011 | B2 |
8070812 | Keller | Dec 2011 | B2 |
8070819 | Aferzon et al. | Dec 2011 | B2 |
8075590 | Janowski | Dec 2011 | B2 |
8075599 | Johnson | Dec 2011 | B2 |
8075603 | Hammill, Sr. | Dec 2011 | B2 |
8075618 | Trieu et al. | Dec 2011 | B2 |
8080062 | Armstrong et al. | Dec 2011 | B2 |
8083796 | Raiszadeh et al. | Dec 2011 | B1 |
8100972 | Bruffey et al. | Jan 2012 | B1 |
8105358 | Phan | Jan 2012 | B2 |
8142479 | Hess | Mar 2012 | B2 |
8142508 | Bruffey et al. | Mar 2012 | B1 |
8147556 | Louis | Apr 2012 | B2 |
8162989 | Khalili | Apr 2012 | B2 |
8167793 | Scott | May 2012 | B2 |
8167950 | Aferzon et al. | May 2012 | B2 |
8187332 | McLuen | May 2012 | B2 |
8192495 | Simpson et al. | Jun 2012 | B2 |
8216313 | Moore | Jul 2012 | B2 |
8221502 | Branch, Jr. | Jul 2012 | B2 |
8231676 | Trudeau et al. | Jul 2012 | B2 |
8241294 | Sommerich et al. | Aug 2012 | B2 |
8241341 | Walker | Aug 2012 | B2 |
8241363 | Sommerich et al. | Aug 2012 | B2 |
8257370 | Moskowitz et al. | Sep 2012 | B2 |
8257439 | Zeegers | Sep 2012 | B2 |
8257443 | Kamran et al. | Sep 2012 | B2 |
8267997 | Colleran | Sep 2012 | B2 |
8273125 | Baccelli | Sep 2012 | B2 |
8292958 | Bruffey et al. | Oct 2012 | B1 |
8328870 | Patel et al. | Dec 2012 | B2 |
8343219 | Allain | Jan 2013 | B2 |
8353913 | Moskowitz et al. | Jan 2013 | B2 |
8361148 | Malberg et al. | Jan 2013 | B2 |
8366774 | Bruffey et al. | Feb 2013 | B1 |
8377133 | Yuan et al. | Feb 2013 | B2 |
8377138 | Reo et al. | Feb 2013 | B2 |
8388688 | Moore | Mar 2013 | B2 |
8394145 | Weiman | Mar 2013 | B2 |
8398713 | Weiman | Mar 2013 | B2 |
8409285 | Keller | Apr 2013 | B2 |
8425528 | Berry et al. | Apr 2013 | B2 |
8435296 | Kadaba et al. | May 2013 | B2 |
8435301 | Gerber et al. | May 2013 | B2 |
8444696 | Michelson | May 2013 | B2 |
8454623 | Patel et al. | Jun 2013 | B2 |
8460388 | Kirwan | Jun 2013 | B2 |
8491658 | Etminan | Jul 2013 | B1 |
8512407 | Butler et al. | Aug 2013 | B2 |
8512409 | Mertens et al. | Aug 2013 | B1 |
8518120 | Glerum | Aug 2013 | B2 |
8523909 | Hess | Sep 2013 | B2 |
8523946 | Swann | Sep 2013 | B1 |
8540769 | Janowski et al. | Sep 2013 | B2 |
8545562 | Materna et al. | Oct 2013 | B1 |
8545563 | Brun et al. | Oct 2013 | B2 |
8556979 | Glerum et al. | Oct 2013 | B2 |
8579982 | Michelson | Nov 2013 | B2 |
8597353 | Kana et al. | Dec 2013 | B2 |
8597357 | Trudeau et al. | Dec 2013 | B2 |
8597360 | McLuen et al. | Dec 2013 | B2 |
8617245 | Brett | Dec 2013 | B2 |
8679183 | Glerum | Mar 2014 | B2 |
8685098 | Glerum | Apr 2014 | B2 |
8685104 | Lee et al. | Apr 2014 | B2 |
8696751 | Ashley et al. | Apr 2014 | B2 |
8698405 | Kirwan | Apr 2014 | B2 |
8709086 | Glerum | Apr 2014 | B2 |
8715350 | Janowski et al. | May 2014 | B2 |
8734516 | Moskowitz et al. | May 2014 | B2 |
8747444 | Moskowitz et al. | Jun 2014 | B2 |
8753394 | Zipnick et al. | Jun 2014 | B2 |
8795335 | Abdou et al. | Aug 2014 | B1 |
8795367 | Zipnick | Aug 2014 | B2 |
8795368 | Trieu et al. | Aug 2014 | B2 |
8814879 | Trieu et al. | Aug 2014 | B2 |
8828018 | Ragab et al. | Sep 2014 | B2 |
8845738 | Michelson | Sep 2014 | B2 |
8858638 | Michelson | Oct 2014 | B2 |
8864829 | Bruffey et al. | Oct 2014 | B1 |
8864833 | Glerum | Oct 2014 | B2 |
8888853 | Glerum | Nov 2014 | B2 |
8888854 | Glerum | Nov 2014 | B2 |
8894710 | Simpson et al. | Nov 2014 | B2 |
8900310 | Carlson et al. | Dec 2014 | B2 |
8906101 | Lee et al. | Dec 2014 | B2 |
8920505 | Aferzon et al. | Dec 2014 | B2 |
8932355 | Grotz et al. | Jan 2015 | B2 |
8932359 | Brett | Jan 2015 | B2 |
8940048 | Butler et al. | Jan 2015 | B2 |
8956413 | Ashley et al. | Feb 2015 | B2 |
8961605 | Zipnick | Feb 2015 | B2 |
8968405 | Kirwan et al. | Mar 2015 | B2 |
8979933 | Vishnubholta et al. | Mar 2015 | B2 |
8986384 | Malberg et al. | Mar 2015 | B2 |
8992620 | Ashley et al. | Mar 2015 | B2 |
8998920 | Berry et al. | Apr 2015 | B2 |
9005293 | Moskowitz et al. | Apr 2015 | B2 |
9034041 | Wolters et al. | May 2015 | B2 |
9039770 | Aferzon et al. | May 2015 | B2 |
9039771 | Glerum | May 2015 | B2 |
9107760 | Walters | Aug 2015 | B2 |
9107761 | Lee et al. | Aug 2015 | B2 |
9114020 | Arginteanu | Aug 2015 | B2 |
9119732 | Schifano et al. | Sep 2015 | B2 |
9155553 | Zipnick | Oct 2015 | B2 |
9168152 | Raiszadeh et al. | Oct 2015 | B2 |
9186262 | McLuen et al. | Nov 2015 | B2 |
9198764 | Greenberg et al. | Dec 2015 | B2 |
9198771 | Ciupik | Dec 2015 | B2 |
9198774 | Pisharodi | Dec 2015 | B2 |
9211196 | Glerum | Dec 2015 | B2 |
9220606 | Janowski et al. | Dec 2015 | B2 |
9226836 | Glerum | Jan 2016 | B2 |
9233011 | Trudeau et al. | Jan 2016 | B2 |
9248028 | Gamache | Feb 2016 | B2 |
9283085 | Greenberg et al. | Mar 2016 | B2 |
9283087 | Lee et al. | Mar 2016 | B2 |
9289308 | Marino et al. | Mar 2016 | B2 |
9301854 | Moskowitz et al. | Apr 2016 | B2 |
9351847 | Reed et al. | May 2016 | B2 |
9364342 | Walkenhorst et al. | Jun 2016 | B2 |
9370435 | Walkenhorst et al. | Jun 2016 | B2 |
9375239 | Abdou | Jun 2016 | B2 |
9463091 | Brett | Oct 2016 | B2 |
9707100 | Duffield et al. | Jul 2017 | B2 |
9730802 | Harvey | Aug 2017 | B1 |
10307265 | Sack | Jun 2019 | B2 |
10369007 | Laurence et al. | Aug 2019 | B2 |
10524930 | Duffield | Jan 2020 | B2 |
10765531 | Kim et al. | Sep 2020 | B2 |
11246716 | Sack | Feb 2022 | B2 |
20020120272 | Yuan | Aug 2002 | A1 |
20030004511 | Ferree | Jan 2003 | A1 |
20030109928 | Pasquet | Jun 2003 | A1 |
20030125742 | Yuan | Jul 2003 | A1 |
20030135279 | Michelson | Jul 2003 | A1 |
20030149484 | Michelson | Aug 2003 | A1 |
20030187433 | Lin | Oct 2003 | A1 |
20030187434 | Lin | Oct 2003 | A1 |
20030187436 | Bolget et al. | Oct 2003 | A1 |
20040010312 | Enayati | Jan 2004 | A1 |
20040133280 | Trieu | Jul 2004 | A1 |
20040153068 | Janowski | Aug 2004 | A1 |
20040236330 | Purcell | Nov 2004 | A1 |
20040254644 | Taylor | Dec 2004 | A1 |
20050027362 | Williams et al. | Feb 2005 | A1 |
20050033296 | Bono | Feb 2005 | A1 |
20050033429 | Kuo | Feb 2005 | A1 |
20050049590 | Alleyne et al. | Mar 2005 | A1 |
20050060036 | Schultz et al. | Mar 2005 | A1 |
20050107788 | Beaurain | May 2005 | A1 |
20050125062 | Biedermann | Jun 2005 | A1 |
20050131410 | Lin | Jun 2005 | A1 |
20050143825 | Enayati | Jun 2005 | A1 |
20050177154 | Moumene | Aug 2005 | A1 |
20050187548 | Butler | Aug 2005 | A1 |
20050197760 | Kaga | Sep 2005 | A1 |
20050228385 | Iott | Oct 2005 | A1 |
20050283157 | Coates | Dec 2005 | A1 |
20050288671 | Yuan | Dec 2005 | A1 |
20060004357 | Lee | Jan 2006 | A1 |
20060025767 | Khalili | Feb 2006 | A1 |
20060069436 | Sutton et al. | Mar 2006 | A1 |
20060095136 | McLuen | May 2006 | A1 |
20060122701 | Kiester | Jun 2006 | A1 |
20060129149 | Iott | Jun 2006 | A1 |
20060149241 | Richelsoph | Jul 2006 | A1 |
20060161152 | Ensign | Jul 2006 | A1 |
20060217716 | Baker | Sep 2006 | A1 |
20060241764 | Michelson | Oct 2006 | A1 |
20060247636 | Yuan | Nov 2006 | A1 |
20060247776 | Kim | Nov 2006 | A1 |
20060264933 | Baker | Nov 2006 | A1 |
20060276789 | Jackson | Dec 2006 | A1 |
20060276899 | Zipnick et al. | Dec 2006 | A1 |
20060276901 | Zipnick et al. | Dec 2006 | A1 |
20060276902 | Zipnick et al. | Dec 2006 | A1 |
20060282074 | Renaud | Dec 2006 | A1 |
20060293665 | Shluzas | Dec 2006 | A1 |
20070050032 | Gittings et al. | Mar 2007 | A1 |
20070055235 | Janowski | Mar 2007 | A1 |
20070055241 | Matthis | Mar 2007 | A1 |
20070088357 | Johnson | Apr 2007 | A1 |
20070161999 | Biedermann | Jul 2007 | A1 |
20070162130 | Rashbaum | Jul 2007 | A1 |
20070213731 | Prusmack | Sep 2007 | A1 |
20070233078 | Justis | Oct 2007 | A1 |
20070233080 | Na | Oct 2007 | A1 |
20070239160 | Zipnick | Oct 2007 | A1 |
20070270813 | Garamszegi | Nov 2007 | A1 |
20070270960 | Bonin et al. | Nov 2007 | A1 |
20070270961 | Ferguson | Nov 2007 | A1 |
20070282341 | Hes | Dec 2007 | A1 |
20080015580 | Chao | Jan 2008 | A1 |
20080015584 | Richelsoph | Jan 2008 | A1 |
20080015597 | Whipple | Jan 2008 | A1 |
20080021562 | Huppert | Jan 2008 | A1 |
20080027550 | Link et al. | Jan 2008 | A1 |
20080045953 | Garamszegi | Feb 2008 | A1 |
20080045955 | Berrevoets | Feb 2008 | A1 |
20080051901 | deVilliers | Feb 2008 | A1 |
20080051902 | Dwyer | Feb 2008 | A1 |
20080133017 | Beyar et al. | Jun 2008 | A1 |
20080147121 | Justis | Jun 2008 | A1 |
20080161930 | Carls | Jul 2008 | A1 |
20080167716 | Schwartz et al. | Jul 2008 | A1 |
20080177322 | Davis | Jul 2008 | A1 |
20080177332 | Reiley | Jul 2008 | A1 |
20080183215 | Altarac | Jul 2008 | A1 |
20080195159 | Kloss | Aug 2008 | A1 |
20080200956 | Beckwith | Aug 2008 | A1 |
20080234686 | Beaurain | Sep 2008 | A1 |
20080287998 | Doubler | Nov 2008 | A1 |
20080294203 | Kovach | Nov 2008 | A1 |
20080312743 | Vila | Dec 2008 | A1 |
20090030457 | Janowski | Jan 2009 | A1 |
20090036929 | Reglos | Feb 2009 | A1 |
20090062866 | Jackson | Mar 2009 | A1 |
20090082819 | Blain | Mar 2009 | A1 |
20090105832 | Allain | Apr 2009 | A1 |
20090164020 | Janowski et al. | Jun 2009 | A1 |
20090182430 | Tyber | Jul 2009 | A1 |
20090198241 | Phan | Aug 2009 | A1 |
20090198245 | Phan | Aug 2009 | A1 |
20090198338 | Phan | Aug 2009 | A1 |
20090265007 | Colleran | Oct 2009 | A1 |
20090265008 | Thibodeau | Oct 2009 | A1 |
20090270992 | Gerber et al. | Oct 2009 | A1 |
20090292316 | Hess | Nov 2009 | A1 |
20090306720 | Doubler | Dec 2009 | A1 |
20090318974 | Yuan | Dec 2009 | A1 |
20100004694 | Little | Jan 2010 | A1 |
20100010547 | Beaurain | Jan 2010 | A1 |
20100016974 | Janowski | Jan 2010 | A1 |
20100063552 | Chin | Mar 2010 | A1 |
20100094352 | Iott | Apr 2010 | A1 |
20100100185 | Trieu | Apr 2010 | A1 |
20100114318 | Gittings et al. | May 2010 | A1 |
20100137920 | Hammill | Jun 2010 | A1 |
20100137989 | Armstrong | Jun 2010 | A1 |
20100145455 | Simpson et al. | Jun 2010 | A1 |
20100145459 | McDonough et al. | Jun 2010 | A1 |
20100161057 | Berry et al. | Jun 2010 | A1 |
20100185289 | Kirwan | Jul 2010 | A1 |
20100185292 | Hochschuler | Jul 2010 | A1 |
20100191246 | Howald et al. | Jul 2010 | A1 |
20100198273 | Kwak | Aug 2010 | A1 |
20100204737 | Bae | Aug 2010 | A1 |
20100217395 | Bertagnoli | Aug 2010 | A1 |
20100249933 | Trieu | Sep 2010 | A1 |
20100249935 | Slivka et al. | Sep 2010 | A1 |
20100268280 | Yuan | Oct 2010 | A1 |
20100280618 | Jodaitis | Nov 2010 | A1 |
20100305704 | Messerli et al. | Dec 2010 | A1 |
20100312279 | Gephart | Dec 2010 | A1 |
20110009911 | Hammill | Jan 2011 | A1 |
20110015742 | Hong | Jan 2011 | A1 |
20110015745 | Bucci | Jan 2011 | A1 |
20110035007 | Patel | Feb 2011 | A1 |
20110077739 | Rashbaum | Mar 2011 | A1 |
20110093074 | Glerum et al. | Apr 2011 | A1 |
20110098747 | Donner | Apr 2011 | A1 |
20110106166 | Keyer | May 2011 | A1 |
20110112587 | Patel | May 2011 | A1 |
20110118840 | Huntsman | May 2011 | A1 |
20110125196 | Quevedo | May 2011 | A1 |
20110137349 | Moskowitz et al. | Jun 2011 | A1 |
20110144701 | Altarac | Jun 2011 | A1 |
20110160779 | Schlaepfer | Jun 2011 | A1 |
20110160866 | Laurence | Jun 2011 | A1 |
20110166655 | Michelson | Jul 2011 | A1 |
20110172774 | Varela | Jul 2011 | A1 |
20110196431 | Chao | Aug 2011 | A1 |
20110196494 | Yedlicka et al. | Aug 2011 | A1 |
20110202135 | Baek et al. | Aug 2011 | A1 |
20110208250 | Kwak | Aug 2011 | A1 |
20110208311 | Janowski | Aug 2011 | A1 |
20110208312 | Moskowitz et al. | Aug 2011 | A1 |
20110218579 | Jackson | Sep 2011 | A1 |
20110230970 | Lynn | Sep 2011 | A1 |
20110230971 | Donner | Sep 2011 | A1 |
20110270325 | Keyer | Nov 2011 | A1 |
20110307016 | Reglos | Dec 2011 | A1 |
20110313528 | Laubert | Dec 2011 | A1 |
20110319997 | Glerum | Dec 2011 | A1 |
20120010714 | Moskowitz et al. | Jan 2012 | A1 |
20120016477 | Metcalf et al. | Jan 2012 | A1 |
20120029569 | Iott | Feb 2012 | A1 |
20120029578 | Suh | Feb 2012 | A1 |
20120029644 | Markworth et al. | Feb 2012 | A1 |
20120035729 | Glerum | Feb 2012 | A1 |
20120053693 | Zeegers | Mar 2012 | A1 |
20120078371 | Gamache | Mar 2012 | A1 |
20120078373 | Gamache | Mar 2012 | A1 |
20120095559 | Woods | Apr 2012 | A1 |
20120109318 | Gittings | May 2012 | A1 |
20120116466 | Dinville | May 2012 | A1 |
20120143341 | Zipnick | Jun 2012 | A1 |
20120150300 | Nihalani | Jun 2012 | A1 |
20120150304 | Glerum | Jun 2012 | A1 |
20120150305 | Glerum | Jun 2012 | A1 |
20120158146 | Glerum | Jun 2012 | A1 |
20120158148 | Glerum | Jun 2012 | A1 |
20120185049 | Varela | Jul 2012 | A1 |
20120191196 | Louis | Jul 2012 | A1 |
20120215315 | Hochschuler | Aug 2012 | A1 |
20120265248 | Delecrin | Oct 2012 | A1 |
20120265258 | Garvey | Oct 2012 | A1 |
20120277867 | Kana | Nov 2012 | A1 |
20120277868 | Walters | Nov 2012 | A1 |
20120277878 | Sommerich et al. | Nov 2012 | A1 |
20120296428 | Donner | Nov 2012 | A1 |
20120303064 | Walker | Nov 2012 | A1 |
20120330417 | Zipnick | Dec 2012 | A1 |
20120330419 | Moskowitz et al. | Dec 2012 | A1 |
20120330424 | Zeegers | Dec 2012 | A1 |
20120330425 | Zipnick | Dec 2012 | A1 |
20130013006 | Rashbaum | Jan 2013 | A1 |
20130018468 | Moskowitz et al. | Jan 2013 | A1 |
20130018469 | Moskowitz et al. | Jan 2013 | A1 |
20130023991 | Moskowitz et al. | Jan 2013 | A1 |
20130041408 | Dinville | Feb 2013 | A1 |
20130053891 | Hawkins | Feb 2013 | A1 |
20130053962 | Moskowitz et al. | Feb 2013 | A1 |
20130062713 | Li | Mar 2013 | A1 |
20130110242 | Kirwan | May 2013 | A1 |
20130150968 | Dinville | Jun 2013 | A1 |
20130150969 | Zipnick | Jun 2013 | A1 |
20130166029 | Dinville | Jun 2013 | A1 |
20130245767 | Lee | Sep 2013 | A1 |
20130268076 | Carlson | Oct 2013 | A1 |
20130274883 | McLuen et al. | Oct 2013 | A1 |
20130310935 | Swann | Nov 2013 | A1 |
20130338776 | Jones | Dec 2013 | A1 |
20140074241 | McConnell | Mar 2014 | A1 |
20140088711 | Chin | Mar 2014 | A1 |
20140100663 | Messerli et al. | Apr 2014 | A1 |
20140114420 | Robinson | Apr 2014 | A1 |
20140121773 | Patel | May 2014 | A1 |
20140148904 | Robinson | May 2014 | A1 |
20140148905 | Messerli et al. | May 2014 | A1 |
20140163682 | Iott | Jun 2014 | A1 |
20140163683 | Seifert et al. | Jun 2014 | A1 |
20140172104 | Dugal et al. | Jun 2014 | A1 |
20140180417 | Bergey | Jun 2014 | A1 |
20140236297 | Iott | Aug 2014 | A1 |
20140249629 | Moskowitz et al. | Sep 2014 | A1 |
20140277509 | Robinson et al. | Sep 2014 | A1 |
20140277510 | Robinson et al. | Sep 2014 | A1 |
20140303731 | Glerum | Oct 2014 | A1 |
20140324171 | Glerum | Oct 2014 | A1 |
20140371795 | Hess et al. | Dec 2014 | A1 |
20140379085 | Duffield et al. | Dec 2014 | A1 |
20150012097 | Ibarra | Jan 2015 | A1 |
20150018952 | Ali | Jan 2015 | A1 |
20150025637 | Moskowitz et al. | Jan 2015 | A1 |
20150039089 | Balasubramanian | Feb 2015 | A1 |
20150045893 | Dinville et al. | Feb 2015 | A1 |
20150100127 | Bal et al. | Apr 2015 | A1 |
20150105824 | Moskowitz et al. | Apr 2015 | A1 |
20150127107 | Kim | May 2015 | A1 |
20150127109 | Brett et al. | May 2015 | A1 |
20150134064 | Grotz et al. | May 2015 | A1 |
20150142116 | Aferzon et al. | May 2015 | A1 |
20150202051 | Tanaka | Jul 2015 | A1 |
20150209089 | Chataigner | Jul 2015 | A1 |
20150250603 | Glerum | Sep 2015 | A9 |
20150250611 | Schifano et al. | Sep 2015 | A1 |
20150250612 | Schifano et al. | Sep 2015 | A1 |
20150265415 | Gittings et al. | Sep 2015 | A1 |
20150265416 | Aferzon et al. | Sep 2015 | A1 |
20150272743 | Jimenez et al. | Oct 2015 | A1 |
20150289988 | Ashley et al. | Oct 2015 | A1 |
20150305880 | Kim et al. | Oct 2015 | A1 |
20150305887 | McAtamney et al. | Oct 2015 | A1 |
20150320568 | Ameil et al. | Nov 2015 | A1 |
20150335372 | Schifano et al. | Nov 2015 | A1 |
20150342754 | Geebelen et al. | Dec 2015 | A1 |
20150374507 | Wolters et al. | Dec 2015 | A1 |
20160015526 | Ali | Jan 2016 | A1 |
20160030191 | McLuen et al. | Feb 2016 | A1 |
20160038299 | Chen et al. | Feb 2016 | A1 |
20160038845 | Mizunaga | Feb 2016 | A1 |
20160045326 | Hansen et al. | Feb 2016 | A1 |
20160045327 | Robinson et al. | Feb 2016 | A1 |
20160058565 | Zappacosta | Mar 2016 | A1 |
20160074172 | Lee et al. | Mar 2016 | A1 |
20160081813 | Greenberg et al. | Mar 2016 | A1 |
20160100953 | Dinville et al. | Apr 2016 | A1 |
20160106550 | Slivka et al. | Apr 2016 | A1 |
20160113777 | Gamache | Apr 2016 | A1 |
20160120657 | Trudeau et al. | May 2016 | A1 |
20160166395 | Weiman | Jun 2016 | A9 |
20160175107 | Janowski et al. | Jun 2016 | A1 |
20160374831 | Duffield | Dec 2016 | A1 |
20170056192 | Buss | Mar 2017 | A1 |
20170165082 | Faulhaber | Jun 2017 | A1 |
20170246008 | Mercier | Aug 2017 | A1 |
20170266016 | Faulhaber | Sep 2017 | A1 |
20170296238 | Snell et al. | Oct 2017 | A1 |
20180104068 | Sack | Apr 2018 | A1 |
20180110627 | Sack | Apr 2018 | A1 |
20180296359 | Sack | Oct 2018 | A1 |
Number | Date | Country |
---|---|---|
2012-201234 | Jan 2012 | JP |
2015-501189 | Jan 2015 | JP |
2015054235 | Mar 2015 | JP |
2015-077467 | Apr 2015 | JP |
2015-514514 | May 2015 | JP |
2016-524988 | Aug 2016 | JP |
2019-535360 | Dec 2019 | JP |
WO 2010092893 | Aug 2010 | WO |
2012047289 | Apr 2012 | WO |
2012117312 | Sep 2012 | WO |
2013062716 | May 2013 | WO |
2016010499 | Jan 2016 | WO |
WO 2016210434 | Dec 2016 | WO |
Entry |
---|
International Search Report and Written Opinion dated Aug. 25, 2016 in PCT/US2016/039642. |
Office Action dated Oct. 3, 2016 in U.S. Appl. No. 15/194,323. |
Office Action dated Jul. 14, 2017 in U.S. Appl. No. 15/623,463 |
Office Action dated Mar. 4, 2019 in Chinese. Application No. 2016800372853. |
Office Action dated Nov. 1, 2019 in Chinese Application No. 2016800372853. |
Office Action dated May 7, 2020 in Chinese Application No. 2016800372853. |
Office Action dated Oct. 12, 2018 in European Application No. 16738939.4. |
Office Action dated Mar. 28, 2019 in japanese Application No. 2017-561910. |
Notice of Allowance dated Dec. 5, 2019 in Japan Application No. 2017-561910. |
Office Action dated Nov. 16, 2018 in U.S. Appl. No. 15/885,230. |
Final Office Action dated May 30, 2019 in U.S. Appl. No. 15/885,230. |
Notice of Allowance dated Aug. 28, 2019 in U.S. Appl. No. 15/885,230. |
Office Action dated Jun. 29, 2022 in U.S. Appl. No. 16/735,384. |
Notice of Allowance dated Feb. 10, 2023 in U.S. Appl. No. 16/735,384. |
Office Action dated Sep. 26, 2018 in U.S. Appl. No. 15/333,892. |
Final Office Action dated Feb. 15, 2019 in U.S. Appl. No. 15/333,892. |
Notice of Allowance dated May 1, 2019 in U.S. Appl. No. 15/333,892. |
Office Action dated Aug. 26, 2021 in U.S. Appl. No. 16/565,003. |
Final Office Action dated Dec. 10, 2021 in U.S. Appl. No. 16/565,003. |
Office Action dated Aug. 12, 2022 in U.S. Appl. No. 16/565,003. |
Preliminary Office Action dated Feb. 15, 2022 in Brazilian Application No. 1120190083235. |
Office Action dated Nov. 30, 2020 in Chinese. Application No. 2017800805892. |
Office Action dated Jun. 17, 2021 in Chinese. Application No. 2017800805892. |
Notice of Allowance dated Sep. 15, 2021 in Chinese Application No. 2017800805892. |
Partial Search Report and Written Opinion dated Jun. 19, 2020 in European Application 17885409.1. |
Extended European Search Report dated Nov. 6, 2020 in European Application 17885409.1. |
Office Action dated Mar. 2, 2023 in Japanese Application No. 2022-012078. |
Office Action dated Jan. 5, 2021 in Japanese Application No. 2019-543189. |
Notice of Allowance dated Dec. 2, 2021 in Japanese Application No. |
International Search Report and Written Opinion dated Jan. 23, 2018 in PCT/US2017/058109. |
Office Action dated Nov. 15, 2018 in U.S. Appl. No. 15/791,194. |
Final Office Action dated Mar. 5, 2019 in U.S. Appl. No. 15/791,194. |
Notice of Allowance dated Jun. 10, 2019 in U.S. Appl. No. 15/791,194. |
Office Action dated Oct. 21, 2021 in U.S. Appl. No. 16/659,031. |
Notice of Allowance dated Apr. 6, 2022 in U.S. Appl. No. 16/659,031 |
Office Action dated Sep. 7, 2018 in U.S. Appl. No. 15/296,902. |
Notice of Allowance dated Jan. 22, 2019 in U.S. Appl. No. 15/296,902 |
Office Action dated Jun. 24, 2021 in U.S. Appl. No. 16/429,278. |
Notice of Allowance dated Oct. 6, 2021 in U.S. Appl. No. 16/429,278. |
Office Action dated Mar. 10, 2023 in U.S. Appl. No. 16/429,278. |
Preliminary Office Action dated Feb. 15, 2022 in Brazilian Application No. 1120190080163. |
Office Action dated Dec. 30, 2020 in Chinese. Application No. 2017800781366. |
Notice of Allowance dated Sep. 16, 2021 in Chinese Application No. 2017800781366. |
Partial Search Report and Written Opinion dated Jun. 23, 2020 in European Application 17863072.9. |
Extended European Search Report dated Sep. 30, 2020 in European Application 17863072.9. |
Office Action dated Mar. 30, 2023 in Japanese Application No. 2022-062252. |
Office Action dated Sep. 3, 2020 in Japanese Application No. 2019-520880. |
Office Action dated Jun. 3, 2021 in Japanese Application No. 2019-520880. |
Notice of Allowance dated Feb. 3, 2022 in Japanese Application No. 2019-520880. |
International Search Report and Written Opinion dated Jan. 12, 2018 in PCT/US2017/056973. |
Office Action dated Apr. 9, 2020 in U.S. Appl. No. 16/109,326. |
Notice of Allowance dated Jul. 29, 2020 in U.S. Appl. No. 16/109,326. |
International Search Report and Written Opinion dated Dec. 18, 2019 in PCT/US2019/047714. |
Office Action dated Jun. 9, 2020 in U.S. Appl. No. 15/996,189. |
Final Office Action dated Oct. 8, 2020 in U.S. Appl. No. 15/996,189. |
Notice of Allowance dated Jan. 22, 2021 in U.S. Appl. No. 15/996,189. |
Office Action dated Feb. 7, 2023 in U.S. Appl. No. 17/322,312. |
International Search Report and Written Opinion dated Aug. 25, 2016 for International Application No. PCT/US2016/039642. |
Number | Date | Country | |
---|---|---|---|
20220133494 A1 | May 2022 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16429278 | Jun 2019 | US |
Child | 17577926 | US | |
Parent | 15296902 | Oct 2016 | US |
Child | 16429278 | US |